-
Je něco špatně v tomto záznamu ?
Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity
J. Soukup, T. Cesak, H. Hornychova, M. Manethova, L. Michnova, D. Netuka, B. Vitovcova, J. Cap, A. Ryska, F. Gabalec
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
NV19-01-00435
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
33738859
DOI
10.1111/his.14366
Knihovny.cz E-zdroje
- MeSH
- hypofýza patologie MeSH
- keratin-8 analýza MeSH
- nádorové biomarkery analýza MeSH
- nádory hypofýzy * klasifikace patologie MeSH
- neuroendokrinní nádory * klasifikace patologie MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: In somatotroph pituitary neuroendocrine tumours (adenomas), a pattern of cytokeratin (CK) 18 expression is used for tumour subclassification, with possible clinical implications. Rare somatotroph tumours do not express CK 18. We aimed to characterise this subset clinically and histologically. METHODS AND RESULTS: Clinical and pathological data for the study were derived from a previously published data set of a cohort of 110 patients with acromegaly. Data included serum levels of insulin-like growth factor 1 (IGF1), growth hormone (GH), prolactin and thyroid-stimulating hormone (TSH), tumour diameter, tumour invasion defined by Knosp grade and immunohistochemical data concerning the expression of Ki67, p53, E-cadherin, somatostatin receptor (SSTR)1, SSTR2A, SSTR3, SSTR5 and D2 dopamine receptor. Additional immunohistochemical analysis (AE1/3, CK 8/18, vimentin, neurofilament light chain, internexin-α) was performed. CK 18 was negative in 10 of 110 (9.1%) tumours. One of these tumours was immunoreactive with CK 8/18 antibody, while the remainder expressed only internexin-α intermediate filament in patterns similar to CK 18 (perinuclear fibrous bodies). CK-negative tumours showed no significant differences with respect to biochemical, radiological or pathological features. They showed significantly higher expression of SSTR2A compared to the sparsely granulated subtype and significantly lower expression of E-cadherin compared to the non-sparsely granulated subtypes of tumours. The tumours showed divergent morphology and hormonal expression: two corresponded to densely granulated tumours and three showed co-expression of prolactin and morphology of either mammosomatotroph or somatotroph-lactotroph tumours. Four tumours showed morphology and immunoprofile compatible with plurihormonal Pit1-positive tumours. CONCLUSIONS: CK-negative somatotroph tumours do not represent a distinct subtype of somatotroph tumours, and can be further subdivided according to their morphology and immunoprofile.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003815
- 003
- CZ-PrNML
- 005
- 20220127145828.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/his.14366 $2 doi
- 035 __
- $a (PubMed)33738859
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Soukup, Jiri $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 245 10
- $a Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity / $c J. Soukup, T. Cesak, H. Hornychova, M. Manethova, L. Michnova, D. Netuka, B. Vitovcova, J. Cap, A. Ryska, F. Gabalec
- 520 9_
- $a AIMS: In somatotroph pituitary neuroendocrine tumours (adenomas), a pattern of cytokeratin (CK) 18 expression is used for tumour subclassification, with possible clinical implications. Rare somatotroph tumours do not express CK 18. We aimed to characterise this subset clinically and histologically. METHODS AND RESULTS: Clinical and pathological data for the study were derived from a previously published data set of a cohort of 110 patients with acromegaly. Data included serum levels of insulin-like growth factor 1 (IGF1), growth hormone (GH), prolactin and thyroid-stimulating hormone (TSH), tumour diameter, tumour invasion defined by Knosp grade and immunohistochemical data concerning the expression of Ki67, p53, E-cadherin, somatostatin receptor (SSTR)1, SSTR2A, SSTR3, SSTR5 and D2 dopamine receptor. Additional immunohistochemical analysis (AE1/3, CK 8/18, vimentin, neurofilament light chain, internexin-α) was performed. CK 18 was negative in 10 of 110 (9.1%) tumours. One of these tumours was immunoreactive with CK 8/18 antibody, while the remainder expressed only internexin-α intermediate filament in patterns similar to CK 18 (perinuclear fibrous bodies). CK-negative tumours showed no significant differences with respect to biochemical, radiological or pathological features. They showed significantly higher expression of SSTR2A compared to the sparsely granulated subtype and significantly lower expression of E-cadherin compared to the non-sparsely granulated subtypes of tumours. The tumours showed divergent morphology and hormonal expression: two corresponded to densely granulated tumours and three showed co-expression of prolactin and morphology of either mammosomatotroph or somatotroph-lactotroph tumours. Four tumours showed morphology and immunoprofile compatible with plurihormonal Pit1-positive tumours. CONCLUSIONS: CK-negative somatotroph tumours do not represent a distinct subtype of somatotroph tumours, and can be further subdivided according to their morphology and immunoprofile.
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a keratin-8 $x analýza $7 D053533
- 650 12
- $a neuroendokrinní nádory $x klasifikace $x patologie $7 D018358
- 650 _2
- $a hypofýza $x patologie $7 D010902
- 650 12
- $a nádory hypofýzy $x klasifikace $x patologie $7 D010911
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cesak, Tomas $u Department of Neurosurgery, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Hornychova, Helena $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Manethova, Monika $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Michnova, Ludmila $u Department of Pathology, Military University Hospital Prague, Praha, Czech Republic
- 700 1_
- $a Netuka, David $u Department of Neurosurgery and Neurooncology, 1st Medical Faculty, Charles University, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Vitovcova, Barbora $u Department of Medical Biology and Genetics, Faculty of Medicine Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Cap, Jan $u 4th Department of Internal Medicine, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Ryska, Ales $u The Fingerland Department of Pathology, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Gabalec, Filip $u 4th Department of Internal Medicine, Faculty of Medicine Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
- 773 0_
- $w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 79, č. 3 (2021), s. 406-415
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33738859 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145825 $b ABA008
- 999 __
- $a ok $b bmc $g 1751320 $s 1154964
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 79 $c 3 $d 406-415 $e 20210521 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043
- GRA __
- $a NV19-01-00435 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20220113
